Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Imunosuppression Trial (BENEFIT)

This study is designed for adults who receive a kidney transplant. It is designed to compare standard anti-rejection medicine to an experimental anti-rejection medicine, Belatacept. It will look carefully at how well the anti-rejection medicine works and if it may be potentially less harmful to the transplanted kidney. Participants will be randomly assigned to receive standard medicine (cyclosporine) or the experimental medicine (Belatacept).

• Individuals undergoing a kidney transplant with the organ from either a living related donor or an organ through the United Network for Organ Sharing (UNOS).
• Other eligibility criteria may apply. Please contact study coordinator.

• Current enrollment in another research study
• Other exclusion criteria may apply. Please contact study coordinator.